10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: to

Commission file number: 01-07698

ACME UNITED CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Connecticut	06-0236700
State or Other Jurisdiction of	I.R.S. Employer Identification No.
Incorporation or Organization
1 Waterview Drive, Shelton, Connecticut	06484
Address of Principal Executive Offices	Zip Code

Registrant's telephone number, including area code: (203) 254-6060

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
$2.50 par value Common Stock	ACU	NYSE American

Indicate by check mark whether the registrant (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (sec. 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller Reporting Company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(s) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Registrant had 3,810,359 shares of its $2.50 par value Common Stock outstanding as of April 30, 2026.

ACME UNITED CORPORATION

INDEX

		Page Number
Part I — FINANCIAL INFORMATION:		3
Item 1:	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets at March 31, 2026 and December 31, 2025	3
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025	5
	Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2026 and 2025	6
	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2026 and 2025	7
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3:	Quantitative and Qualitative Disclosures about Market Risk	20
Item 4:	Controls and Procedures	20
Part II — OTHER INFORMATION:		21
Item 1:	Legal Proceedings	21
Item 1A:	Risk Factors	21
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3:	Defaults Upon Senior Securities	21
Item 4:	Mine Safety Disclosures	21
Item 5:	Other Information	21
Item 6:	Exhibits	21
Signatures		22

2

Part I - FINANCIAL INFORMATION

Item 1: Financial Statements

ACME UNITED CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(all amounts in thousands)

	March 31,		December 31,
	2026		2025
	(unaudited)		(Note 1)
ASSETS
Current assets:
Cash and cash equivalents	$	4,196	$	3,596
Accounts receivable, less allowance for credit losses of $527 in 2026 and $494 in 2025		33,511		29,098
Inventories		63,386		59,852
Prepaid expenses and other current assets		4,518		3,649
Total current assets		105,611		96,195
Property, plant and equipment:
Land		3,487		3,487
Buildings		24,051		24,051
Machinery and equipment		45,339		43,462
		72,877		71,000
Less: accumulated depreciation		33,582		32,459
Net property, plant and equipment		39,295		38,541
Operating lease right-of-use asset, net		6,408		6,881
Goodwill		9,908		9,908
Intangible assets, less accumulated amortization		34,021		19,473
Total assets	$	195,243	$	170,998

See Notes to Unaudited Condensed Consolidated Financial Statements.

3

ACME UNITED CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

(all amounts in thousands, except par value and share amounts)

	March 31,			December 31,
	2026			2025
	(unaudited)			(Note 1)
LIABILITIES
Current liabilities:
Accounts payable	$	7,654		$	8,065
Operating lease liability - current portion		1,373			1,446
Current portion of mortgage payable		458			454
Other current liabilities		13,619			12,906
Total current liabilities		23,104			22,871
Non-current liabilities:
Long-term debt		33,030			11,853
Mortgage payable, net of current portion		9,362			9,432
Operating lease liability - non-current portion		5,176			5,532
Deferred income taxes		3,685			3,685
Other non-current liabilities		4,159			14
Total liabilities		78,516			53,387
Commitments and contingencies (see note 2)
STOCKHOLDERS' EQUITY
Common stock, par value $2.50:
authorized 8,000,000 shares;
5,355,231 shares issued and 3,810,359 shares outstanding in 2026 and
5,351,596 shares issued and 3,806,724 shares outstanding in 2025		13,388			13,379
Additional paid-in capital		18,451			19,506
Retained earnings		102,668			102,293
Treasury stock, at cost - 1,544,872 shares in 2026 and 2025		(15,996	)		(15,996	)
Accumulated other comprehensive loss:
Translation adjustment		(1,784	)		(1,571	)
Total stockholders’ equity		116,727			117,611
Total liabilities and stockholders’ equity	$	195,243		$	170,998

See Notes to Unaudited Condensed Consolidated Financial Statements.

4

ACME UNITED CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

(all amounts in thousands, except per share amounts)

	Three Months Ended March 31,
	2026		2025
Net sales	$	52,301	$	45,958
Cost of goods sold		31,516		28,041
Gross profit		20,785		17,917
Selling, general and administrative expenses		19,039		15,491
Operating income		1,746		2,426
Non-operating items:
Interest expense, net		486		397
Other expense (income) , net		16		(90	)
Income before income tax expense		1,244		2,119
Income tax expense		259		466
Net income	$	985	$	1,653
Basic earnings per share	$	0.26	$	0.44
Diluted earnings per share	$	0.24	$	0.41
Weighted average number of common shares outstanding-denominator used for basic per share computations		3,808		3,754
Weighted average number of dilutive stock options outstanding		348		311
Denominator used for diluted per share computations		4,156		4,065
Dividends declared per share	$	0.16	$	0.15

See Notes to Unaudited Condensed Consolidated Financial Statements.

5

ACME UNITED CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

(all amounts in thousands)

	Three Months Ended
	March 31,
	2026			2025
Net income	$	985		$	1,653
Other comprehensive (loss) income:
Foreign currency translation adjustment		(213	)		261
Comprehensive income	$	772		$	1,914

See Notes to Unaudited Condensed Consolidated Financial Statements.

6

ACME UNITED CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(UNAUDITED)

(all amounts in thousands, except share amounts)

For the three months ended March 31, 2025

	Outstanding Shares of Common Stock		Common Stock		Treasury  Stock			Additional Paid-In Capital			Accumulated  Other Comprehensive Loss			Retained Earnings			Total
December 31, 2024		3,754,498	$	13,248	$	(15,996	)	$	17,981		$	(2,751	)	$	94,498		$	106,980
Net income															1,653			1,653
Other comprehensive income												261						261
Stock compensation expense									413									413
Distributions to stockholders															(563	)		(563	)
Cash settlement of stock options									(463	)								(463	)
March 31, 2025		3,754,498		13,248	$	(15,996	)		17,931			(2,490	)		95,588			108,281

For the three months ended March 31, 2026

	Outstanding Shares of Common Stock		Common Stock		Treasury  Stock			Additional Paid-In Capital			Accumulated  Other Comprehensive Loss			Retained Earnings			Total
December 31, 2025		3,806,724	$	13,379	$	(15,996	)	$	19,506		$	(1,571	)	$	102,293		$	117,611
Net income															985			985
Other comprehensive (loss)												(213	)					(213	)
Stock compensation expense									319									319
Distributions to stockholders															(610	)		(610	)
Issuance of common stock		2,876		7					90									97
Cash settlement of stock options									(1,462	)								(1,462	)
Net share settlement of stock options		759		2					(2	)								(0	)
March 31, 2026		3,810,359		13,388	$	(15,996	)		18,451			(1,784	)		102,668			116,727

See Notes to Unaudited Condensed Consolidated Financial Statements.

7

ACME UNITED CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(all amounts in thousands)

	Three Months Ended
	March 31,
	2026			2025
Cash flows from operating activities:
Net income	$	985		$	1,653
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		1,156			863
Amortization of intangible assets		815			638
Non-cash lease adjustment		46			(2	)
Stock compensation expense		319			413
Provision for credit losses		30			8
Provision for excess and obsolete inventory		-			140
Amortization of deferred financing costs		30			10
Changes in operating assets and liabilities:
Accounts receivable		(4,166	)		(2,468	)
Inventories		(1,068	)		(941	)
Prepaid expenses and other assets		(638	)		(725	)
Accounts payable		(794	)		(1,798	)
Other accrued liabilities		1,052			(1,128	)
Total adjustments		(3,218	)		(4,990	)
Net cash used in operating activities		(2,233	)		(3,337	)
Cash flows from investing activities:
Purchase of property, plant and equipment		(1,889	)		(1,353	)
Acquisition of My Medic		(14,412	)		-
Net cash used in investing activities		(16,301	)		(1,353	)
Cash flows from financing activities:
Net borrowings of long-term debt		21,159			2,816
Cash settlement of stock options		(1,462	)		(463	)
Repayments on mortgage		(77	)		(99	)
Proceeds from issuance of common stock		97			-
Distributions to shareholders		(610	)		(563	)
Net cash provided by financing activities		19,107			1,691
Effect of exchange rate changes on cash and cash equivalents		27			46
Net change in cash and cash equivalents		600			(2,953	)
Cash and cash equivalents at beginning of period		3,596			6,399
Cash and cash equivalents at end of period	$	4,196		$	3,446
Supplemental cash flow information:
Cash paid for income taxes	$	80		$	85
Cash paid for interest	$	380		$	368

See Notes to Unaudited Condensed Consolidated Financial Statements.

8

ACME UNITED CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. Basis of Presentation

The accompanying condensed consolidated financial statements include all adjustments necessary to present fairly the financial position, results of operations and cash flows of Acme United Corporation (the “Company”). These adjustments are of a normal, recurring nature. However, the financial statements do not include all the disclosures normally required by accounting principles generally accepted in the United States or those normally made in the Company's Annual Report on Form 10-K. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2025 for such disclosures. The condensed consolidated balance sheet as of December 31, 2025 was derived from the audited consolidated balance sheet as of that date. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Company’s 2025 Annual Report on Form 10-K.

The Company has evaluated events and transactions subsequent to March 31, 2026 and through the date these condensed consolidated financial statements were issued.

Recently Issued Accounting Standards

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, intangible asset amortization and depletion) included in certain expense captions presented on the face of the income statement. The ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods beginning after December 15, 2027. The ASU may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements and early adoption is permitted. The Company is evaluating the potential impact of adopting this ASU on our consolidated financial statements and related disclosures.

2. Commitment and Contingencies

There are no pending material legal proceedings to which the Company is a party, or, to the actual knowledge of the Company, contemplated by any governmental authority.

3. Revenue from Contracts with Customers

Nature of Goods and Services

The Company recognizes revenue from the sales of a broad line of products that are grouped into two main categories: (a) first aid and medical; and (b) cutting and sharpening. The first aid and medical category includes first aid kits and refills, over-the-counter medications and a variety of medical products. The cutting and sharpening category includes scissors, knives, paper trimmers, pencil sharpeners and other sharpening tools. Revenue recognition is evaluated through the following five steps: (i) identification of the contract or contracts with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

When Performance Obligations Are Satisfied

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Revenue is generated by the sale of the Company’s products to its customers. Sales contracts (purchase orders) generally have a single performance obligation that is satisfied at a point in time, upon shipment or delivery, depending on the terms of the underlying contract. Revenue is measured based on the consideration specified in the contract. The amount of consideration we receive and revenue we recognize is impacted by incentives ("customer rebates"), including sales rebates, which are generally tied to sales volume levels, in-store promotional allowances, shared media and customer catalog allowances and other cooperative advertising arrangements; freight allowance programs offered to our customers; and allowance for returns and discounts. We generally recognize customer rebate costs as a deduction to gross sales at the time that the associated revenue is recognized.

9

Significant Payment Terms

Payment terms for each customer are dependent on the agreed upon contractual repayment terms. Payment terms typically are between 30 and 90 days and vary depending on the size of the customer and its risk profile to the Company. Some customers receive discounts for early payment.

Product Returns

The Company accepts product returns in the normal course of business. The Company estimates reserves for returns and the related refunds to customers based on historical experience. Reserves for returned merchandise are included as a component of “Accounts receivable” in the condensed consolidated balance sheets.

Practical Expedient Usage and Accounting Policy Elections

For the Company’s contracts that have an original duration of one year or less, the Company uses the practical expedient in ASC 606-10-32-18 applicable to such contracts and does not consider the time value of money in relation to significant financing components.

Per ASC 606-10-25-18B, the Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity instead of a performance obligation. Furthermore, shipping and handling activities performed before transfer of control of the product also do not constitute a separate and distinct performance obligation.

The Company has elected to exclude from the transaction price those amounts which relate to sales and other taxes that are assessed by governmental authorities and that are imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer.

Applying the practical expedient in ASC 340-40-25-4, Other Assets and Deferred Costs, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred. These costs are included in “Selling, general and administrative expenses.”

Disaggregation of Revenues

The following table represents external net sales disaggregated by product category, by segment (amounts in thousands):

For the three months ended March 31, 2026

	United States		Canada		Europe		Total
First Aid and Medical	$	33,581	$	2,999	$	492	$	37,072
Cutting and Sharpening		10,187		701		4,341		15,229
Total Net Sales	$	43,768	$	3,700	$	4,833	$	52,301

For the three months ended March 31, 2025

	United States		Canada		Europe		Total
First Aid and Medical	$	28,164	$	2,514	$	325	$	31,003
Cutting and Sharpening		10,958		671		3,326		14,955
Total Net Sales	$	39,122	$	3,185	$	3,651	$	45,958

4. Debt and Stockholders’ Equity

Long-term debt consists of (i) borrowings under the Company’s revolving loan agreement with HSBC Bank USA, N.A. (“HSBC”) and (ii) amounts outstanding under the fixed rate mortgage on the Company’s manufacturing and distribution facilities in Rocky Mount, NC and Vancouver, WA. Effective as of June 26, 2025, the Company entered into Amendment No. 11 to the Revolving Loan Agreement dated as of April 5, 2012, as amended (the ”Loan Agreement”), between the Company and HSBC. Amendment No. 11 extended the scheduled maturity of the $65 million dollar secured revolving credit facility under the Loan Agreement to May 31, 2027. The terms of the Loan Agreement otherwise remain unchanged. The Loan Agreement provides for borrowings of up to $65 million at an interest rate of Secured Overnight Financing Rate (“SOFR”) plus a margin of +1.75%; interest is payable monthly. The Company must pay a facility fee, payable quarterly, in an amount equal to one eighth of one percent (.125%) per annum of the average daily unused portion of the revolving credit line. The facility is intended to provide liquidity for operating activities, growth, acquisitions, dividends, share repurchases and other business activities. Under the Loan Agreement, the Company is required to maintain a specific ratio of funded debt to EBITDA, a fixed charge coverage ratio and must have annual net income greater than $0, measured as of the end of each fiscal year. As of March 31, 2026, the Company was in compliance with the covenants under the Loan Agreement as then in effect.

As of March 31, 2026 and December 31, 2025, the Company had outstanding borrowings under the Loan Agreement of $33,034,000 and $11,863,000, excluding deferred financing costs of $4,000 and $10,299, respectively.

10

The Company’s manufacturing and distribution facilities in Rocky Mount, NC and Vancouver, WA were financed by a mortgage with HSBC at a fixed interest rate of 3.8%. The Company entered into the agreement on December 1, 2021. Commencing on January 1, 2022, payments of principal and interest are due monthly, with all amounts outstanding due on maturity on December 1, 2031. As of March 31, 2026 and December 31, 2025, long-term debt related to the mortgage consisted of the following (amounts in ‘000’s):

	March 31, 2026			December 31, 2025
Mortgage payable - HSBC Bank N.A.	$	9,906		$	9,976
Less debt issuance costs		(86	)		(90	)
		9,820			9,886
Less current maturities		458			454
Long-term mortgage payable less current maturities	$	9,362		$	9,432

During the three months ended March 31, 2026, the Company issued a total of 2,876 shares of common stock and received aggregate proceeds of $97,000 upon exercise of employee stock options. During the three months ended March 31, 2026, the Company paid approximately $1,462,000 to optionees who had elected (subject to the approval of the Company) a net cash settlement of certain of their respective options. In addition, during the three months ended March 31, 2026, the Company issued a total of 759 shares of common stock to optionees who had elected (subject to the approval of the Company) a net share settlement of certain of their respective options.

5. Segment Information

The Company aligns its businesses into three reportable business segments based on geographical location. This segment structure reflects (i) the manner in which the Chief Operating Decision Maker (“CODM”), who is the Company’s Chief Executive Officer, regularly assesses information for decision-making purposes, including the allocation of resources, and (ii) how the Company operates its businesses, assesses performance, and communicates results and strategy, among other items, to the Board and its stockholders.

The Company’s reportable business segments consist of: (1) United States; (2) Canada; and (3) Europe. As described below, the activities of the Company’s Asian operations are closely linked to those of the U.S. operations; accordingly, the Company’s CODM reviews the financial results of both on a consolidated basis, and the results of the Asian operations have been aggregated with the results of the United States operations to form one reportable segment called the “United States segment” or “U.S. segment”. Each reportable segment derives its revenue from the sales of i) first aid and medical products and ii) cutting and sharpening tools to school, home, office, hardware, sporting and industrial markets.

The Company's CODM evaluates the performance of each operating segment based on segment revenues and operating income. Segment revenues are defined as total revenues, excluding inter-segment revenue. Segment operating earnings are defined as segment revenues, less cost of goods sold and operating expenses. Assets are reviewed by the CODM on a consolidated basis and therefore are not presented by reportable business segment.

11

The following tables sets forth certain financial data by segment for the three months ended March 31, 2026 and 2025:

For the three months ended March 31, 2026
(amounts in 000's)
	United States		Canada		Europe		Total
Net Sales	$	43,768	$	3,700	$	4,833	$	52,301
Less: Segment cost of sales		26,659		2,135		2,722		31,516
Less: Segment selling, general, and administrative expenses		16,070		1,318		1,651		19,039
Segment operating income	$	1,039	$	247	$	460	$	1,746
Interest expense, net								(486	)
Other expense, net								(16	)
Income before income taxes							$	1,244
Assets		171,504		10,766		12,973		195,243
Additions to property, plant and equipment		1,824		4		61		1,889
Depreciation and amortization		1,882		27		62		1,971
For the three months ended March 31, 2025
(amounts in 000's)
	United States		Canada		Europe		Total
Net Sales	$	39,122	$	3,185	$	3,651	$	45,958
Less: Segment cost of sales		23,700		1,985		2,356		28,041
Less: Segment selling, general, and administrative expenses		13,063		1,159		1,269		15,491
Segment operating income	$	2,359	$	41	$	26	$	2,426
Interest expense, net								(397	)
Other income, net								90
Income before income taxes							$	2,119
Assets		143,808		9,713		9,518		163,039
Additions to property, plant and equipment		1,334		18		1		1,353
Depreciation and amortization		1,444		44		12		1,501

6. Stock Based Compensation

The Company recognizes share-based compensation at the fair value of the equity instrument on the grant date. Compensation expense is recognized over the required service period, which is generally the vesting period of the equity instrument. Share-based compensation expense was approximately $319,000 for the three months ended March 31, 2026, compared to approximately $413,000 for the three months ended March 31, 2025.

As of March 31, 2026, there was a total of $3,328,608 of unrecognized compensation cost, adjusted for estimated forfeitures, related to non-vested share-based payments granted to the Company’s employees. As of that date, the remaining unamortized expense was expected to be recognized over a weighted average period of approximately three years.

7. Fair Value Measurements

The carrying value of the Company’s bank debt is a reasonable estimate of fair value because of the nature of its payment terms and maturity.

8. Leases

The Company has operating leases for office and warehouse space and equipment under various arrangements which provide the right to use the underlying asset and require lease payments for the lease term. The Company’s lease portfolio consists of operating leases which expire at various dates through 2033.

Certain of the Company’s lease arrangements contain renewal provisions, exercisable at the Company's option. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with right-of-use (“ROU”) assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease.

12

Operating lease cost was $0.5 million for the three months ended March 31, 2026, of which $0.2 million was included in cost of goods sold and $0.3 million was included in selling, general and administrative expenses.

Information related to leases (in thousands):

	Three Months Ended		Three Months Ended
Operating cash flow information:	March 31, 2026		March 31, 2025
Operating lease cost	$	513	$	461
Operating lease - cash flow	$	468	$	464

	March 31, 2026			March 31, 2025
Weighted-average remaining lease term	6.0 years			4.0 years
Weighted-average discount rate		7	%		7	%

Future minimum lease payments under non-cancelable leases as of March 31, 2026:

2026 (remaining)		1,357
2027		1,668
2028		1,697
2029		993
2030		639
Thereafter		1,438
Total future minimum lease payments	$	7,792
Less: imputed interest		(1,243	)
Present value of lease liabilities - current		1,373
Present value of lease liabilities - non-current	$	5,176

9. Other Accrued Liabilities

Other current and non-current accrued liabilities consisted of (in thousands):

	March 31,		December 31,
	2026		2025
Customer rebates	$	7,543	$	6,863
Holdback Liability - My Medic asset acquisition		3,143		—
Accrued compensation		2,487		2,950
Contingent liability - My Medic asset acquisition		1,000		—
Dividend payable		610		609
Other		2,995		2,498
Total:	$	17,778	$	12,920

10. Intangible Assets and Goodwill

The Company’s intangible assets and goodwill consisted of (in thousands):

13

	March 31,			December 31,
	2026			2025
Tradename	$	12,909		$	12,909
Customer list		21,114			21,114
Non-compete		1,667			1,667
Patents		2,272			2,272
My Medic intangible assets		15,409			-
Subtotal		53,371			37,962
Less: Accumulated amortization		19,281			18,465
Translation adjustments		(69	)		(24	)
Intangible assets	$	34,021		$	19,473
Goodwill	$	9,908		$	9,908
Total:	$	43,929		$	29,381

The useful lives of the identifiable intangible assets range from 5 years to 15 years.

11. Inventories

Inventories consisted of (in thousands):

	March 31,		December 31,
	2026		2025
Finished goods	$	49,937	$	44,751
Work in process		395		305
Materials and supplies		13,054		14,796
	$	63,386	$	59,852

Inventories are stated at the lower of cost or net realizable value, determined by the first-in, first-out method.

12. Business Combination

On January 15, 2026, the Company acquired the assets of SLED Distribution, LLC. (d/b/a "My Medic"), a leading supplier of tactical, trauma and emergency response products, primarily in the direct-to-consumer channel, pursuant to an Asset Purchase agreement of the same date.

The purchase price of the acquisition was $18.6 million. At closing, the Company paid $14.4 million in cash to My Medic. Payment of the $4.1 million balance of the purchase price is subject to certain contingencies as follows: (a) $1,000,000, the payment of which is contingent upon the achievement of certain revenue milestones during the twelve months ended December 31, 2027; and (b) $3.1 million, which is subject to a holdback as a non-exclusive source of recovery primarily to satisfy indemnification claims under the Asset Purchase Agreement, which claims must be made within various time periods depending on the nature of the claim. The $3.1 million holdback and $1.0 million contingent payment are reported in other long term liabilities on the condensed consolidated balance sheet.

The preliminary purchase price was allocated to assets acquired as follows (in thousands):

Assets:
Accounts Receivable	$	238
Inventory		2,662
Prepaid Expense		223
Property, Plant & Equipment		21
Intangibles		15,409
Total assets	$	18,553

The acquisition was accounted for as a business combination, pursuant to ASC 805 – Business Combinations. All assets acquired in the acquisition are included in the Company’s United States operating segment. Management’s assessment of the fair values of assets acquired and liabilities assumed, including identifiable intangible assets and goodwill, is preliminary and subject to change during the measurement period (which will not exceed one year from the acquisition date). Adjustments to the preliminary allocation may result from additional information obtained regarding facts and circumstances that existed as of the acquisition date

.

14

The results of My Medic have been included in the Company’s condensed consolidated financial statements since the acquisition date. For the three months ended March 31, 2026, My Medic contributed revenue of $3.4 million.

15

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information

The Company may from time to time make written or oral “forward-looking statements” including statements contained in this report and in other communications by the Company, which are made in good faith pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on our beliefs as well as assumptions made by and information currently available to us. When used in this document, words like “may,” “might,” “will,” “expect,” “anticipate,” “believe,” “potential,” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from our current expectations.

Forward-looking statements in this report, including without limitation, statements related to the Company’s plans, strategies, objectives, expectations, intentions and adequacy of resources, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties that may impact the Company’s business, operations and financial results.

These risks and uncertainties include, without limitation, the following: (i) changes in the Company’s plans, strategies, objectives, expectations and intentions, which may be made at any time at the discretion of the Company; (ii) the impact of volatility in global economic conditions, including the impact on the Company’s suppliers and customers; (iii) international trade policies of the United States or foreign governments and their impact on demand for our products and our competitive position, including the imposition of new tariffs, changes in existing tariff rates or the threat of any such action; (iv) potential adverse effects on the Company, its customers, and suppliers resulting from the wars in Iran and elsewhere in the Middle East and Ukraine; (v) the continuing adverse impact of inflation, including product costs, transportation costs and interest rates; (vi) additional disruptions in the Company’s supply chains, whether caused by pandemics, natural disasters, including trucker shortages, port closures, port strikes or otherwise; (vii) labor related costs the Company has and may continue to incur, including costs of acquiring and training new employees and rising wages and benefits; (viii) changes in client needs and consumer spending habits; (ix) currency fluctuations; (x) the Company’s ability to effectively manage its inventory in a rapidly changing business environment; (xi) the impact of competition; (xii) the impact of technological changes including, specifically, the growth of online marketing and sales activity; (xiii) the Company’s ability to manage its growth effectively, including its ability to successfully integrate any business it might acquire; ; and (xiv) other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission.

For a more detailed discussion of these and other factors affecting the Company, see the Risk Factors described in Item 1A included in the Company’s Annual Report on Form 10-K for the fiscal year December 31, 2025 and below under “Financial Condition”. All forward-looking statements in this report are based upon information available to the Company on the date of this report. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Critical Accounting Estimates

There have been no material changes to the Company’s critical accounting estimates as previously reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Results of Operations

Traditionally, the Company’s sales and profits are stronger in the second and third quarters and weaker in the first and fourth quarters of the fiscal year, due to the seasonal nature of the Westcott back-to-school market.

Net sales

Consolidated net sales for the three months ended March 31, 2026 were $52,301,000 compared to $45,958,000 in the same period in 2025, an increase of 14%. Excluding the incremental sales resulting from the acquisition of the assets of My Medic on January 15, 2026, comparable sales increased 6%.

Net sales in the U.S. for the three months ended March 31, 2026 increased 12% compared to the same period in 2025. The increase in net sales for the three months ended March 31, 2026 was primarily due to increased sales of first aid and medical products and additional sales resulting from the acquisition of the assets of My Medic.

Net sales in Canada for the three months ended March 31, 2026 increased 16% in U.S. dollars and 11% in local currency compared to the same period in 2025 due to higher sales of first aid products.

16

European net sales for the three months ended March 31, 2026 increased 32% in U.S. dollars and 19% in local currency compared to the same period in 2025 primarily due to higher ecommerce sales and additional sales resulting from the acquisition of the cutting and sharpening line of products on October 1, 2025.

Gross profit

Gross profit for the three months ended March 31, 2026 was $20,785,000 (39.7% of net sales) compared to $17,917,000 (39.0% of net sales) in the same period in 2025.

Selling, general and administrative expenses

Selling, general and administrative ("SG&A") expenses for the three months ended March 31, 2026 were $19,039,000 (36.4% of net sales) compared with $15,491,000 (33.7% of net sales) in the same period in 2025, an increase of $3,548,000. The increase in SG&A expenses was primarily due to the acquisition of the assets of My Medic as well as higher personnel related expenses.

Operating income

Operating income for the three months ended March 31, 2026 was $1,746,000 compared with $2,426,000 in the same period of 2025.

Operating income in the U.S. segment decreased by $1,320,000 for the three months ended March 31, 2026 compared to the same period in 2025. The decrease in operating income for the three months ended March 31, 2026 was primarily due to higher cost of sales and increased operating expenses as a result of higher tariff-related costs and investments in enhanced quality assurance protocols at the Med-Nap facility, together with rising employee healthcare expenses. Tariff expenses were recognized during the first quarter as the Company sold inventory that had been subject to the high tariff rates imposed in 2025.

Operating income in the Canadian segment increased by $206,000 for the three months ended March 31, 2026, compared to the same period in 2025. The increase in operating income for the three months ended March 31, 2026 was primarily due to higher sales of first aid products.

Operating income in the European segment increased by $434,000 for the three months ended March 31, 2026, compared to the same period in 2025. The increase in operating income for the three months ended March 31, 2026 was primarily due to higher sales.

Interest expense, net

Interest expense, net for the three months ended March 31, 2026 was $486,000 compared with $397,000 in the same period of 2025, an $89,000 increase. The increase in interest expense for the three months ended March 31, 2026 resulted from higher average outstanding borrowings partially offset by lower average interest rates on the debt outstanding.

Other income (expense), net

Other expense, net was $16,000 in the three months ended March 31, 2026 compared to other income of $90,000 in the same period of 2025.

Income taxes

The effective income tax rate for the three months ended March 31, 2026 was 21% compared to 22% in the same period of 2025.

Financial Condition

Liquidity and Capital Resources

During the first three months of 2026, working capital increased approximately $9.2 million. Inventory turnover, calculated using a twelve-month average inventory balance, was 2.0 at March 31, 2026 and December 31, 2025. Receivables increased approximately $4.4 million at March 31, 2026 compared to December 31, 2025. The average number of days sales outstanding in accounts receivable was 51 days at March 31, 2026 compared to 54 days at December 31, 2025. Accounts payable and other current liabilities increased by approximately $0.3 million at March 31, 2026 compared to December 31, 2025.

17

The Company's working capital, current ratio and long-term debt to equity ratio are as follows (dollar amounts in thousands):

	March 31,			December 31,
	2026			2025
Working capital	$	82,507		$	73,324
Current ratio		4.57			4.21
Long term debt to equity ratio		36.3	%		18.1	%

Long-term debt consists of (i) borrowings under the Company’s revolving loan agreement with HSBC Bank, N.A. and (ii) amounts outstanding under the fixed rate mortgage on the Company’s manufacturing and distribution facilities in Rocky Mount, NC and Vancouver, WA. Effective as of June 26, 2025, the Company entered into Amendment No. 11 to the Loan Agreement. Amendment No. 11 extends the scheduled maturity of the $65 million dollar secured revolving credit facility under the Loan Agreement to May 31, 2027. The Loan Agreement provides for borrowings of up to $65 million, at an interest rate of SOFR plus 1.75%; interest is payable monthly. The Loan Agreement has an expiration date of May 31, 2027. The Company must pay a facility fee, payable quarterly, in an amount equal to one eighth of one percent (.125%) per annum of the average daily unused portion of the revolving credit line. The facility is intended to provide liquidity for operating activities, growth, acquisitions, dividends share repurchases and other business activities. Under the revolving loan agreement, the Company is required to maintain specific amounts of funded debt to EBITDA, a fixed charge coverage ratio and must have annual net income greater than $0, measured as of the end of each fiscal year. As of March 31, 2026, the Company was in compliance with the covenants under the revolving loan agreement as then in effect.

During the first three months of 2026, total debt outstanding under the Company’s revolving credit facility increased by approximately $21.2 million, compared to total debt thereunder at December 31, 2025. As of March 31, 2026, $33,034,000 was outstanding and $31,966,000 was available for borrowing under the Company’s credit facility.

On January 15, 2026, the Company acquired the assets of SLED Distribution, LLC. (d/b/a "My Medic") a leading supplier of tactical, trauma and emergency response products sold primarily through the direct-to-consumer channel, for approximately $18.7 million,

On July 15, 2025, the Company purchased a manufacturing and distribution center in Mt. Pleasant, TN for approximately $6.0 million. The property consists of 77,000 square feet of manufacturing and warehouse space on 12 acres and is designed to be expanded by up to an additional 60,000 square feet. The facility is used primarily to manufacture our Spill Magic line of bodily fluid and spill clean up solutions.

The Company’s manufacturing and distribution facilities in Rocky Mount, NC and Vancouver, WA were financed by a fixed rate mortgage with HSBC Bank, N.A. at a rate of 3.8%. The Company entered into the mortgage loan agreement on December 1, 2021. Payments of principal and interest are due monthly, with all amounts outstanding due on maturity on December 1, 2031. At March 31, 2026, there was approximately $9.9 million outstanding on the mortgage.

Our operations, supply chains, and financial performance are impacted by evolving global trade policies and tariffs, and geopolitical tensions and wars, including ongoing conflicts and instability in the Middle East. In particular, our global operations and international sales expose us to risks associated with trade conflicts between the United States and other governments, as well as broader regional instability in the Middle East that can disrupt global shipping routes and energy markets. These factors have resulted in and could continue to result in inflationary costs to produce and sell our products, both domestically and in foreign markets.

The higher tariff expenses during the first quarter of 2026 resulted from the Company selling inventory that had been subject to high tariff rates imposed in 2025. We expect that the impact of tariffs on the Company will gradually lessen over the balance of 2026 as the Company begins to sell inventory subject to lower tariffs set in November 2025 and February 2026. In addition, we have commenced purchasing a total of approximately $10 million of inventory for delivery in the second and third quarters of 2026 to mitigate the potential shortages or price increases as a result of the war in Iran or other regional conflicts.

We have been actively diversifying our supply base for many years and source products and components in a number of countries. A significant portion of the products we sell (and components used in our products) are sourced from suppliers located in China. The United States government has imposed, and may continue to impose or adjust, significant tariffs on a range of Chinese goods. These tariffs have increased our costs of goods sold and could further escalate depending on changes in trade policy, negotiations, or retaliatory measures by China or by other countries similarly impacted. The indirect impact on demand for our products as a result of these developments has become more uncertain. The Company has taken and continues to take steps to mitigate the potential impact on our business and operations through strategic sourcing adjustments, price adjustments and supply chain diversification, but such efforts have not been able to fully mitigate the effects of the imposition of tariffs and related developments. Any further increases of existing tariffs, the imposition of new tariffs, the potential modifications to existing trade agreements, new restrictions on free trade and the responses by other governments to changes in trade policy by the United States may further adversely impact demand for our products, increase our costs, and disrupt our supply chain. These risks, in turn, could have a material adverse effect on our business, results of operations, and financial condition.

18

The Company believes that cash generated from operating activities, together with funds available under its revolving loan agreement, will, under current conditions, be sufficient to finance the Company’s operations over the next twelve months from the filing of this report.

19

Item 3: Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4: Controls and Procedures

(a) Evaluation of Internal Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of March 31, 2026. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective.

(b) Changes in Internal Control over Financial Reporting

During the quarter ended March 31, 2026, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

20

PART II. OTHER INFORMATION

Item 1 — Legal Proceedings

There are no pending material legal proceedings to which the registrant is a party, or, to the actual knowledge of the Company, contemplated by any governmental authority.

Item 1A — Risk Factors

See Risk Factors set forth in Part I, Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3 — Defaults upon Senior Securities

None.

Item 4 — Mine Safety Disclosures

Not applicable.

Item 5 — Other Information

None.

Item 6 — Exhibits

Documents filed as part of this report:

Exhibit 31.1	Certification of Walter C. Johnsen pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2	Certification of Paul G. Driscoll pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1	Certification of Walter C. Johnsen pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2	Certification of Paul G. Driscoll pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
104	The cover page for the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101

21

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACME UNITED CORPORATION
By	/s/ Walter C. Johnsen
	Walter C. Johnsen
	Chairman of the Board and
	Chief Executive Officer
Dated: May 6, 2026

By	/s/ Paul G. Driscoll
	Paul G. Driscoll
	Vice President and
	Chief Financial Officer
Dated: May 6, 2026

22

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, WALTER C. JOHNSEN, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Acme United Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

By	/s/ Walter C. Johnsen
	Walter C. Johnsen
	Chairman of the Board and
	Chief Executive Officer

Dated: May 6, 2026

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, PAUL G. DRISCOLL, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Acme United Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

By	/s/ Paul G. Driscoll
	Paul G. Driscoll
	Vice President and
	Chief Financial Officer

Dated: May 6, 2026

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned officer of Acme United Corporation (the “Company”) hereby certifies to my knowledge that the Company’s quarterly report on Form 10-Q for the quarterly period ended March 31, 2026 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed to be a part of the Report or “filed” for any purpose whatsoever.

By	/s/ Walter C. Johnsen
	Walter C. Johnsen
	Chairman of the Board and
	Chief Executive Officer

Dated: May 6, 2026

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Acme United Corporation and will be retained by Acme United Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned officer of Acme United Corporation (the “Company”) hereby certifies to my knowledge that the Company’s quarterly report on Form 10-Q for the quarterly period ended March 31, 2026 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed to be a part of the Report or “filed” for any purpose whatsoever.

By	/s/ Paul G. Driscoll
	Paul G. Driscoll
	Vice President and
	Chief Financial Officer

Dated: May 6, 2026

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Acme United Corporation and will be retained by Acme United Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2026	Apr. 30, 2026
Cover [Abstract]
Entity Registrant Name	ACME UNITED CORP
Entity Central Index Key	0000002098
Document Type	10-Q
Document Period End Date	Mar. 31, 2026
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		3,810,359
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2026
Trading Symbol	ACU
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity File Number	01-07698
Entity Tax Identification Number	06-0236700
Entity Address, Address Line One	1 Waterview Drive
Entity Address, City or Town	Shelton
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06484
City Area Code	203
Local Phone Number	254-6060
Entity Interactive Data Current	Yes
Title of 12(b) Security	$2.50 par value Common Stock
Security Exchange Name	NYSEAMER
Entity Incorporation, State or Country Code	CT
Document Quarterly Report	true
Document Transition Report	false

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 4,196	$ 3,596
Accounts receivable, less allowance for credit losses of $527 in 2026 and $494 in 2025	33,511	29,098
Inventories	63,386	59,852
Prepaid expenses and other current assets	4,518	3,649
Total current assets	105,611	96,195
Property, plant and equipment:
Land	3,487	3,487
Buildings	24,051	24,051
Machinery and equipment	45,339	43,462
Total property, plant and equipment	72,877	71,000
Less: accumulated depreciation	33,582	32,459
Net property, plant and equipment	39,295	38,541
Operating lease right-of-use asset, net	6,408	6,881
Goodwill	9,908	9,908
Intangible assets, less accumulated amortization	34,021	19,473
Total assets	195,243	170,998
Current liabilities:
Accounts payable	7,654	8,065
Operating lease liability - current portion	1,373	1,446
Current portion of mortgage payable	458	454
Other current liabilities	13,619	12,906
Total current liabilities	23,104	22,871
Long-term debt	33,030	11,853
Mortgage payable, net of current portion	9,362	9,432
Operating lease liability - non-current portion	5,176	5,532
Deferred income taxes	3,685	3,685
Other non-current liabilities	4,159	14
Total liabilities	78,516	53,387
Commitments and contingencies (see note 2)
STOCKHOLDERS' EQUITY
Common stock, par value $2.50: authorized 8,000,000 shares; 5,355,231 shares issued and 3,810,359 shares outstanding in 2026 and 5,351,596 shares issued and 3,806,724 shares outstanding in 2025	13,388	13,379
Additional paid-in capital	18,451	19,506
Retained earnings	102,668	102,293
Treasury stock, at cost - 1,544,872 shares in 2026 and 2025	(15,996)	(15,996)
Accumulated other comprehensive loss:
Translation adjustment	(1,784)	(1,571)
Total stockholders’ equity	116,727	117,611		$ 106,980
Total liabilities and stockholders’ equity	$ 195,243	$ 170,998

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
STOCKHOLDERS' EQUITY
Accounts receivable, allowance for credit losses	$ 527	$ 494
Common stock, par value	$ 2.50	$ 2.50
Common stock, shares authorized	8,000,000	8,000,000
Common stock, shares issued	5,355,231	5,351,596
Common stock, shares outstanding	3,810,359	3,806,724
Treasury stock, shares	1,544,872	1,544,872

XML

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Income Statement [Abstract]
Net sales	$ 52,301	$ 45,958
Cost of goods sold	31,516	28,041
Gross profit	20,785	17,917
Selling, general and administrative expenses	19,039	15,491
Operating income	1,746	2,426
Non-operating items:
Interest expense, net	486	397
Other expense (income) , net	16	(90)
Income before income tax expense	1,244	2,119
Income tax expense	259	466
Net income	$ 985	$ 1,653
Basic earnings per share	$ 0.26	$ 0.44
Diluted earnings per share	$ 0.24	$ 0.41
Weighted average number of common shares outstanding-denominator used for basic per share computations	3,808,000	3,754,000
Weighted average number of dilutive stock options outstanding	348,000	311,000
Denominator used for diluted per share computations	4,156,000	4,065,000
Dividends declared per share	$ 0.16	$ 0.15

XML

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Condensed Consolidated Statements Of Comprehensive Loss Income [Abstract]
Net income	$ 985	$ 1,653
Other comprehensive (loss) income:
Foreign currency translation adjustment	(213)	261
Comprehensive income	$ 772	$ 1,914

XML

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings
Beginning Balance at Dec. 31, 2024	$ 106,980	$ 13,248	$ (15,996)	$ 17,981	$ (2,751)	$ 94,498
Beginning Balance, shares at Dec. 31, 2024		3,754,498
Net income	1,653					1,653
Other comprehensive income (loss)	261				261
Stock compensation expense	413			413
Distributions to stockholders	(563)					(563)
Cash settlement of stock options	(463)			(463)
Ending Balance at Mar. 31, 2025	108,281	$ 13,248	(15,996)	17,931	(2,490)	95,588
Ending Balance, shares at Mar. 31, 2025		3,754,498
Beginning Balance at Dec. 31, 2025	$ 117,611	$ 13,379	(15,996)	19,506	(1,571)	102,293
Beginning Balance, shares at Dec. 31, 2025	3,806,724	3,806,724
Net income	$ 985					985
Other comprehensive income (loss)	(213)				(213)
Stock compensation expense	319			319
Distributions to stockholders	(610)					(610)
Issuance of common stock	$ 97	$ 7		90
Issuance of common stock (shares)	2,876	2,876
Cash settlement of stock options	$ (1,462)			(1,462)
Net share settlement of stock options	0	$ 2		(2)
Net share settlement of stock options, (shares)		759
Ending Balance at Mar. 31, 2026	$ 116,727	$ 13,388	$ (15,996)	$ 18,451	$ (1,784)	$ 102,668
Ending Balance, shares at Mar. 31, 2026	3,810,359	3,810,359

XML

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows from operating activities:
Net income	$ 985,000	$ 1,653,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	1,156,000	863,000
Amortization of intangible assets	815,000	638,000
Non-cash lease adjustment	46,000	(2,000)
Stock compensation expense	319,000	413,000
Provision for credit losses	30,000	8,000
Provision for excess and obsolete inventory		140,000
Amortization of deferred financing costs	30,000	10,000
Changes in operating assets and liabilities:
Accounts receivable	(4,166,000)	(2,468,000)
Inventories	(1,068,000)	(941,000)
Prepaid expenses and other assets	(638,000)	(725,000)
Accounts payable	(794,000)	(1,798,000)
Other accrued liabilities	1,052,000	(1,128,000)
Total adjustments	(3,218,000)	(4,990,000)
Net cash used in operating activities	(2,233,000)	(3,337,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(1,889,000)	(1,353,000)
Acquisition of My Medic	(14,412,000)
Net cash used in investing activities	(16,301,000)	(1,353,000)
Cash flows from financing activities:
Net borrowings of long-term debt	21,159,000	2,816,000
Cash settlement of stock options	(1,462,000)	(463,000)
Repayments on mortgage	(77,000)	(99,000)
Proceeds from issuance of common stock	97,000
Distributions to shareholders	(610,000)	(563,000)
Net cash provided by financing activities	19,107,000	1,691,000
Effect of exchange rate changes on cash and cash equivalents	27,000	46,000
Net change in cash and cash equivalents	600,000	(2,953,000)
Cash and cash equivalents at beginning of period	3,596,000	6,399,000
Cash and cash equivalents at end of period	4,196,000	3,446,000
Supplemental cash flow information:
Cash paid for income taxes	80,000	85,000
Cash paid for interest	$ 380,000	$ 368,000

XML

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Pay vs Performance Disclosure
Net Income (Loss)	$ 985	$ 1,653

XML

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1. Basis of Presentation

The accompanying condensed consolidated financial statements include all adjustments necessary to present fairly the financial position, results of operations and cash flows of Acme United Corporation (the “Company”). These adjustments are of a normal, recurring nature. However, the financial statements do not include all the disclosures normally required by accounting principles generally accepted in the United States or those normally made in the Company's Annual Report on Form 10-K. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2025 for such disclosures. The condensed consolidated balance sheet as of December 31, 2025 was derived from the audited consolidated balance sheet as of that date. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Company’s 2025 Annual Report on Form 10-K.

The Company has evaluated events and transactions subsequent to March 31, 2026 and through the date these condensed consolidated financial statements were issued.

Recently Issued Accounting Standards

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, intangible asset amortization and depletion) included in certain expense captions presented on the face of the income statement. The ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods beginning after December 15, 2027. The ASU may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements and early adoption is permitted. The Company is evaluating the potential impact of adopting this ASU on our consolidated financial statements and related disclosures.

XML

Commitment and Contingencies

3 Months Ended

Mar. 31, 2026

Commitments and Contingencies Disclosure [Abstract]

Commitment and Contingencies

2. Commitment and Contingencies

There are no pending material legal proceedings to which the Company is a party, or, to the actual knowledge of the Company, contemplated by any governmental authority.

XML

Revenue from Contracts with Customers

3 Months Ended

Mar. 31, 2026

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

3. Revenue from Contracts with Customers

Nature of Goods and Services

The Company recognizes revenue from the sales of a broad line of products that are grouped into two main categories: (a) first aid and medical; and (b) cutting and sharpening. The first aid and medical category includes first aid kits and refills, over-the-counter medications and a variety of medical products. The cutting and sharpening category includes scissors, knives, paper trimmers, pencil sharpeners and other sharpening tools. Revenue recognition is evaluated through the following five steps: (i) identification of the contract or contracts with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

When Performance Obligations Are Satisfied

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Revenue is generated by the sale of the Company’s products to its customers. Sales contracts (purchase orders) generally have a single performance obligation that is satisfied at a point in time, upon shipment or delivery, depending on the terms of the underlying contract. Revenue is measured based on the consideration specified in the contract. The amount of consideration we receive and revenue we recognize is impacted by incentives ("customer rebates"), including sales rebates, which are generally tied to sales volume levels, in-store promotional allowances, shared media and customer catalog allowances and other cooperative advertising arrangements; freight allowance programs offered to our customers; and allowance for returns and discounts. We generally recognize customer rebate costs as a deduction to gross sales at the time that the associated revenue is recognized.

Significant Payment Terms

Payment terms for each customer are dependent on the agreed upon contractual repayment terms. Payment terms typically are between 30 and 90 days and vary depending on the size of the customer and its risk profile to the Company. Some customers receive discounts for early payment.

Product Returns

The Company accepts product returns in the normal course of business. The Company estimates reserves for returns and the related refunds to customers based on historical experience. Reserves for returned merchandise are included as a component of “Accounts receivable” in the condensed consolidated balance sheets.

Practical Expedient Usage and Accounting Policy Elections

For the Company’s contracts that have an original duration of one year or less, the Company uses the practical expedient in ASC 606-10-32-18 applicable to such contracts and does not consider the time value of money in relation to significant financing components.

Per ASC 606-10-25-18B, the Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity instead of a performance obligation. Furthermore, shipping and handling activities performed before transfer of control of the product also do not constitute a separate and distinct performance obligation.

The Company has elected to exclude from the transaction price those amounts which relate to sales and other taxes that are assessed by governmental authorities and that are imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer.

Applying the practical expedient in ASC 340-40-25-4, Other Assets and Deferred Costs, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred. These costs are included in “Selling, general and administrative expenses.”

Disaggregation of Revenues

The following table represents external net sales disaggregated by product category, by segment (amounts in thousands):

For the three months ended March 31, 2026

	United States		Canada		Europe		Total
First Aid and Medical	$	33,581	$	2,999	$	492	$	37,072
Cutting and Sharpening		10,187		701		4,341		15,229
Total Net Sales	$	43,768	$	3,700	$	4,833	$	52,301

For the three months ended March 31, 2025

	United States		Canada		Europe		Total
First Aid and Medical	$	28,164	$	2,514	$	325	$	31,003
Cutting and Sharpening		10,958		671		3,326		14,955
Total Net Sales	$	39,122	$	3,185	$	3,651	$	45,958

XML

Debt and Stockholders' Equity

3 Months Ended

Mar. 31, 2026

Debt [Abstract]

Debt and Stockholders' Equity

4. Debt and Stockholders’ Equity

Long-term debt consists of (i) borrowings under the Company’s revolving loan agreement with HSBC Bank USA, N.A. (“HSBC”) and (ii) amounts outstanding under the fixed rate mortgage on the Company’s manufacturing and distribution facilities in Rocky Mount, NC and Vancouver, WA. Effective as of June 26, 2025, the Company entered into Amendment No. 11 to the Revolving Loan Agreement dated as of April 5, 2012, as amended (the ”Loan Agreement”), between the Company and HSBC. Amendment No. 11 extended the scheduled maturity of the $65 million dollar secured revolving credit facility under the Loan Agreement to May 31, 2027. The terms of the Loan Agreement otherwise remain unchanged. The Loan Agreement provides for borrowings of up to $65 million at an interest rate of Secured Overnight Financing Rate (“SOFR”) plus a margin of +1.75%; interest is payable monthly. The Company must pay a facility fee, payable quarterly, in an amount equal to one eighth of one percent (.125%) per annum of the average daily unused portion of the revolving credit line. The facility is intended to provide liquidity for operating activities, growth, acquisitions, dividends, share repurchases and other business activities. Under the Loan Agreement, the Company is required to maintain a specific ratio of funded debt to EBITDA, a fixed charge coverage ratio and must have annual net income greater than $0, measured as of the end of each fiscal year. As of March 31, 2026, the Company was in compliance with the covenants under the Loan Agreement as then in effect.

As of March 31, 2026 and December 31, 2025, the Company had outstanding borrowings under the Loan Agreement of $33,034,000 and $11,863,000, excluding deferred financing costs of $4,000 and $10,299, respectively.

The Company’s manufacturing and distribution facilities in Rocky Mount, NC and Vancouver, WA were financed by a mortgage with HSBC at a fixed interest rate of 3.8%. The Company entered into the agreement on December 1, 2021. Commencing on January 1, 2022, payments of principal and interest are due monthly, with all amounts outstanding due on maturity on December 1, 2031. As of March 31, 2026 and December 31, 2025, long-term debt related to the mortgage consisted of the following (amounts in ‘000’s):

	March 31, 2026			December 31, 2025
Mortgage payable - HSBC Bank N.A.	$	9,906		$	9,976
Less debt issuance costs		(86	)		(90	)
		9,820			9,886
Less current maturities		458			454
Long-term mortgage payable less current maturities	$	9,362		$	9,432

During the three months ended March 31, 2026, the Company issued a total of 2,876 shares of common stock and received aggregate proceeds of $97,000 upon exercise of employee stock options. During the three months ended March 31, 2026, the Company paid approximately $1,462,000 to optionees who had elected (subject to the approval of the Company) a net cash settlement of certain of their respective options. In addition, during the three months ended March 31, 2026, the Company issued a total of 759 shares of common stock to optionees who had elected (subject to the approval of the Company) a net share settlement of certain of their respective options.

XML

Segment Information

3 Months Ended

Mar. 31, 2026

Segment Information [Abstract]

Segment Information

5. Segment Information

The Company aligns its businesses into three reportable business segments based on geographical location. This segment structure reflects (i) the manner in which the Chief Operating Decision Maker (“CODM”), who is the Company’s Chief Executive Officer, regularly assesses information for decision-making purposes, including the allocation of resources, and (ii) how the Company operates its businesses, assesses performance, and communicates results and strategy, among other items, to the Board and its stockholders.

The Company’s reportable business segments consist of: (1) United States; (2) Canada; and (3) Europe. As described below, the activities of the Company’s Asian operations are closely linked to those of the U.S. operations; accordingly, the Company’s CODM reviews the financial results of both on a consolidated basis, and the results of the Asian operations have been aggregated with the results of the United States operations to form one reportable segment called the “United States segment” or “U.S. segment”. Each reportable segment derives its revenue from the sales of i) first aid and medical products and ii) cutting and sharpening tools to school, home, office, hardware, sporting and industrial markets.

The Company's CODM evaluates the performance of each operating segment based on segment revenues and operating income. Segment revenues are defined as total revenues, excluding inter-segment revenue. Segment operating earnings are defined as segment revenues, less cost of goods sold and operating expenses. Assets are reviewed by the CODM on a consolidated basis and therefore are not presented by reportable business segment.

The following tables sets forth certain financial data by segment for the three months ended March 31, 2026 and 2025:

For the three months ended March 31, 2026
(amounts in 000's)
	United States		Canada		Europe		Total
Net Sales	$	43,768	$	3,700	$	4,833	$	52,301
Less: Segment cost of sales		26,659		2,135		2,722		31,516
Less: Segment selling, general, and administrative expenses		16,070		1,318		1,651		19,039
Segment operating income	$	1,039	$	247	$	460	$	1,746
Interest expense, net								(486	)
Other expense, net								(16	)
Income before income taxes							$	1,244
Assets		171,504		10,766		12,973		195,243
Additions to property, plant and equipment		1,824		4		61		1,889
Depreciation and amortization		1,882		27		62		1,971
For the three months ended March 31, 2025
(amounts in 000's)
	United States		Canada		Europe		Total
Net Sales	$	39,122	$	3,185	$	3,651	$	45,958
Less: Segment cost of sales		23,700		1,985		2,356		28,041
Less: Segment selling, general, and administrative expenses		13,063		1,159		1,269		15,491
Segment operating income	$	2,359	$	41	$	26	$	2,426
Interest expense, net								(397	)
Other income, net								90
Income before income taxes							$	2,119
Assets		143,808		9,713		9,518		163,039
Additions to property, plant and equipment		1,334		18		1		1,353
Depreciation and amortization		1,444		44		12		1,501

XML

Stock Based Compensation

3 Months Ended

Mar. 31, 2026

Share-Based Payment Arrangement [Abstract]

Stock Based Compensation

6. Stock Based Compensation

The Company recognizes share-based compensation at the fair value of the equity instrument on the grant date. Compensation expense is recognized over the required service period, which is generally the vesting period of the equity instrument. Share-based compensation expense was approximately $319,000 for the three months ended March 31, 2026, compared to approximately $413,000 for the three months ended March 31, 2025.

As of March 31, 2026, there was a total of $3,328,608 of unrecognized compensation cost, adjusted for estimated forfeitures, related to non-vested share-based payments granted to the Company’s employees. As of that date, the remaining unamortized expense was expected to be recognized over a weighted average period of approximately three years.

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2026

Fair Value Measurements [Abstract]

Fair Value Measurements

7. Fair Value Measurements

The carrying value of the Company’s bank debt is a reasonable estimate of fair value because of the nature of its payment terms and maturity.

XML

Leases

3 Months Ended

Mar. 31, 2026

Leases [Abstract]

Leases

8. Leases

The Company has operating leases for office and warehouse space and equipment under various arrangements which provide the right to use the underlying asset and require lease payments for the lease term. The Company’s lease portfolio consists of operating leases which expire at various dates through 2033.

Certain of the Company’s lease arrangements contain renewal provisions, exercisable at the Company's option. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with right-of-use (“ROU”) assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease.

Operating lease cost was $0.5 million for the three months ended March 31, 2026, of which $0.2 million was included in cost of goods sold and $0.3 million was included in selling, general and administrative expenses.

Information related to leases (in thousands):

	Three Months Ended		Three Months Ended
Operating cash flow information:	March 31, 2026		March 31, 2025
Operating lease cost	$	513	$	461
Operating lease - cash flow	$	468	$	464

	March 31, 2026			March 31, 2025
Weighted-average remaining lease term	6.0 years			4.0 years
Weighted-average discount rate		7	%		7	%

Future minimum lease payments under non-cancelable leases as of March 31, 2026:

2026 (remaining)		1,357
2027		1,668
2028		1,697
2029		993
2030		639
Thereafter		1,438
Total future minimum lease payments	$	7,792
Less: imputed interest		(1,243	)
Present value of lease liabilities - current		1,373
Present value of lease liabilities - non-current	$	5,176

XML

Other Accrued Liabilities

3 Months Ended

Mar. 31, 2026

Payables and Accruals [Abstract]

Other Accrued Liabilities

9. Other Accrued Liabilities

Other current and non-current accrued liabilities consisted of (in thousands):

	March 31,		December 31,
	2026		2025
Customer rebates	$	7,543	$	6,863
Holdback Liability - My Medic asset acquisition		3,143		—
Accrued compensation		2,487		2,950
Contingent liability - My Medic asset acquisition		1,000		—
Dividend payable		610		609
Other		2,995		2,498
Total:	$	17,778	$	12,920

XML

Intangible Assets and Goodwill

3 Months Ended

Mar. 31, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

10. Intangible Assets and Goodwill

The Company’s intangible assets and goodwill consisted of (in thousands):

	March 31,			December 31,
	2026			2025
Tradename	$	12,909		$	12,909
Customer list		21,114			21,114
Non-compete		1,667			1,667
Patents		2,272			2,272
My Medic intangible assets		15,409			-
Subtotal		53,371			37,962
Less: Accumulated amortization		19,281			18,465
Translation adjustments		(69	)		(24	)
Intangible assets	$	34,021		$	19,473
Goodwill	$	9,908		$	9,908
Total:	$	43,929		$	29,381

The useful lives of the identifiable intangible assets range from 5 years to 15 years.

XML

Inventories

3 Months Ended

Mar. 31, 2026

Inventory Disclosure [Abstract]

Inventories

11. Inventories

Inventories consisted of (in thousands):

	March 31,		December 31,
	2026		2025
Finished goods	$	49,937	$	44,751
Work in process		395		305
Materials and supplies		13,054		14,796
	$	63,386	$	59,852

Inventories are stated at the lower of cost or net realizable value, determined by the first-in, first-out method.

XML

Business Combination

3 Months Ended

Mar. 31, 2026

Business Combination [Abstract]

Business Combination

12. Business Combination

On January 15, 2026, the Company acquired the assets of SLED Distribution, LLC. (d/b/a "My Medic"), a leading supplier of tactical, trauma and emergency response products, primarily in the direct-to-consumer channel, pursuant to an Asset Purchase agreement of the same date.

The purchase price of the acquisition was $18.6 million. At closing, the Company paid $14.4 million in cash to My Medic. Payment of the $4.1 million balance of the purchase price is subject to certain contingencies as follows: (a) $1,000,000, the payment of which is contingent upon the achievement of certain revenue milestones during the twelve months ended December 31, 2027; and (b) $3.1 million, which is subject to a holdback as a non-exclusive source of recovery primarily to satisfy indemnification claims under the Asset Purchase Agreement, which claims must be made within various time periods depending on the nature of the claim. The $3.1 million holdback and $1.0 million contingent payment are reported in other long term liabilities on the condensed consolidated balance sheet.

The preliminary purchase price was allocated to assets acquired as follows (in thousands):

Assets:
Accounts Receivable	$	238
Inventory		2,662
Prepaid Expense		223
Property, Plant & Equipment		21
Intangibles		15,409
Total assets	$	18,553

The acquisition was accounted for as a business combination, pursuant to ASC 805 – Business Combinations. All assets acquired in the acquisition are included in the Company’s United States operating segment. Management’s assessment of the fair values of assets acquired and liabilities assumed, including identifiable intangible assets and goodwill, is preliminary and subject to change during the measurement period (which will not exceed one year from the acquisition date). Adjustments to the preliminary allocation may result from additional information obtained regarding facts and circumstances that existed as of the acquisition date

.

The results of My Medic have been included in the Company’s condensed consolidated financial statements since the acquisition date. For the three months ended March 31, 2026, My Medic contributed revenue of $3.4 million.

XML

Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2026

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

The following table represents external net sales disaggregated by product category, by segment (amounts in thousands):

For the three months ended March 31, 2026

	United States		Canada		Europe		Total
First Aid and Medical	$	33,581	$	2,999	$	492	$	37,072
Cutting and Sharpening		10,187		701		4,341		15,229
Total Net Sales	$	43,768	$	3,700	$	4,833	$	52,301

For the three months ended March 31, 2025

	United States		Canada		Europe		Total
First Aid and Medical	$	28,164	$	2,514	$	325	$	31,003
Cutting and Sharpening		10,958		671		3,326		14,955
Total Net Sales	$	39,122	$	3,185	$	3,651	$	45,958

XML

Debt and Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2026

Long Term Debt And Stockholders Equity [Abstract]

Schedule of Long-Term Debt

As of March 31, 2026 and December 31, 2025, long-term debt related to the mortgage consisted of the following (amounts in ‘000’s):

	March 31, 2026			December 31, 2025
Mortgage payable - HSBC Bank N.A.	$	9,906		$	9,976
Less debt issuance costs		(86	)		(90	)
		9,820			9,886
Less current maturities		458			454
Long-term mortgage payable less current maturities	$	9,362		$	9,432

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Segment Information Tables [Abstract]

Financial Data By Segment Table

The following tables sets forth certain financial data by segment for the three months ended March 31, 2026 and 2025:

For the three months ended March 31, 2026
(amounts in 000's)
	United States		Canada		Europe		Total
Net Sales	$	43,768	$	3,700	$	4,833	$	52,301
Less: Segment cost of sales		26,659		2,135		2,722		31,516
Less: Segment selling, general, and administrative expenses		16,070		1,318		1,651		19,039
Segment operating income	$	1,039	$	247	$	460	$	1,746
Interest expense, net								(486	)
Other expense, net								(16	)
Income before income taxes							$	1,244
Assets		171,504		10,766		12,973		195,243
Additions to property, plant and equipment		1,824		4		61		1,889
Depreciation and amortization		1,882		27		62		1,971
For the three months ended March 31, 2025
(amounts in 000's)
	United States		Canada		Europe		Total
Net Sales	$	39,122	$	3,185	$	3,651	$	45,958
Less: Segment cost of sales		23,700		1,985		2,356		28,041
Less: Segment selling, general, and administrative expenses		13,063		1,159		1,269		15,491
Segment operating income	$	2,359	$	41	$	26	$	2,426
Interest expense, net								(397	)
Other income, net								90
Income before income taxes							$	2,119
Assets		143,808		9,713		9,518		163,039
Additions to property, plant and equipment		1,334		18		1		1,353
Depreciation and amortization		1,444		44		12		1,501

XML

Leases (Tables)

3 Months Ended

Mar. 31, 2026

Leases Tables [Abstract]

Information Related to Leases

Information related to leases (in thousands):

	Three Months Ended		Three Months Ended
Operating cash flow information:	March 31, 2026		March 31, 2025
Operating lease cost	$	513	$	461
Operating lease - cash flow	$	468	$	464

	March 31, 2026			March 31, 2025
Weighted-average remaining lease term	6.0 years			4.0 years
Weighted-average discount rate		7	%		7	%

Future Minimum Lease Payments

Future minimum lease payments under non-cancelable leases as of March 31, 2026:

2026 (remaining)		1,357
2027		1,668
2028		1,697
2029		993
2030		639
Thereafter		1,438
Total future minimum lease payments	$	7,792
Less: imputed interest		(1,243	)
Present value of lease liabilities - current		1,373
Present value of lease liabilities - non-current	$	5,176

XML

Other Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2026

Payables and Accruals [Abstract]

Accrued Liabilities

Other current and non-current accrued liabilities consisted of (in thousands):

	March 31,		December 31,
	2026		2025
Customer rebates	$	7,543	$	6,863
Holdback Liability - My Medic asset acquisition		3,143		—
Accrued compensation		2,487		2,950
Contingent liability - My Medic asset acquisition		1,000		—
Dividend payable		610		609
Other		2,995		2,498
Total:	$	17,778	$	12,920

XML

Intangible Assets and Goodwill (Tables)

3 Months Ended

Mar. 31, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

The Company’s intangible assets and goodwill consisted of (in thousands):

	March 31,			December 31,
	2026			2025
Tradename	$	12,909		$	12,909
Customer list		21,114			21,114
Non-compete		1,667			1,667
Patents		2,272			2,272
My Medic intangible assets		15,409			-
Subtotal		53,371			37,962
Less: Accumulated amortization		19,281			18,465
Translation adjustments		(69	)		(24	)
Intangible assets	$	34,021		$	19,473
Goodwill	$	9,908		$	9,908
Total:	$	43,929		$	29,381

XML

Inventories (Tables)

3 Months Ended

Mar. 31, 2026

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of (in thousands):

	March 31,		December 31,
	2026		2025
Finished goods	$	49,937	$	44,751
Work in process		395		305
Materials and supplies		13,054		14,796
	$	63,386	$	59,852

XML

Business Combination (Tables)

3 Months Ended

Mar. 31, 2026

Business Combination [Abstract]

Schedule of Preliminary Purchase Price Allocation to Assets Acquired

The preliminary purchase price was allocated to assets acquired as follows (in thousands):

Assets:
Accounts Receivable	$	238
Inventory		2,662
Prepaid Expense		223
Property, Plant & Equipment		21
Intangibles		15,409
Total assets	$	18,553

XML

Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Disaggregation of Revenue [Line Items]
Net sales	$ 52,301	$ 45,958
First Aid and Medical
Disaggregation of Revenue [Line Items]
Net sales	37,072	31,003
Cutting and Sharpening
Disaggregation of Revenue [Line Items]
Net sales	15,229	14,955
United States
Disaggregation of Revenue [Line Items]
Net sales	43,768	39,122
United States | First Aid and Medical
Disaggregation of Revenue [Line Items]
Net sales	33,581	28,164
United States | Cutting and Sharpening
Disaggregation of Revenue [Line Items]
Net sales	10,187	10,958
Canada
Disaggregation of Revenue [Line Items]
Net sales	3,700	3,185
Canada | First Aid and Medical
Disaggregation of Revenue [Line Items]
Net sales	2,999	2,514
Canada | Cutting and Sharpening
Disaggregation of Revenue [Line Items]
Net sales	701	671
Europe
Disaggregation of Revenue [Line Items]
Net sales	4,833	3,651
Europe | First Aid and Medical
Disaggregation of Revenue [Line Items]
Net sales	492	325
Europe | Cutting and Sharpening
Disaggregation of Revenue [Line Items]
Net sales	$ 4,341	$ 3,326

XML

Debt and Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Long Term Debt And Stockholders Equity [Line Items]
Issuance of common stock (shares)	2,876
Outstanding borrowings under revolving loan agreement	$ 33,034,000		$ 11,863,000
Deferred financing cost	4,000		$ 10,299
Cash settlement of stock options	1,462,000	$ 463,000
Aggregate proceeds from exercise of employee stock options	$ 97,000
Common Stock
Long Term Debt And Stockholders Equity [Line Items]
Issuance of common stock (shares)	2,876
Stock issued during period shares new issues related to net share settlement	759
HSBC Bank
Long Term Debt And Stockholders Equity [Line Items]
Credit facility borrowing capacity	$ 65,000,000
Interest rate	1.75%
Investment, Variable Interest Rate, Type [Extensible Enumeration]	us-gaap:SecuredOvernightFinancingRateSofrMember
Credit facility interest rate	Secured Overnight Financing Rate (“SOFR”) plus a margin of +1.75%
Revolving agreement expiration date	May 31, 2027
Facility fee per annum	0.125%
HSBC Bank | Maximum
Long Term Debt And Stockholders Equity [Line Items]
Credit facility borrowing capacity	$ 65,000,000
First Aid Only Distribution Center
Long Term Debt And Stockholders Equity [Line Items]
Covenant terms and compliance	Under the Loan Agreement, the Company is required to maintain a specific ratio of funded debt to EBITDA, a fixed charge coverage ratio and must have annual net income greater than $0, measured as of the end of each fiscal year
Fixed interest rate	3.80%

XML

Debt and Stockholders' Equity - Schedule of Long-Term Debt (Details) - USD ($)	Mar. 31, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
Less debt issuance costs	$ (4,000)	$ (10,299)
Long-term mortgage payable less current maturities	33,030,000	11,853,000
Mortgage Payable - HSBC Bank N.A.
Debt Instrument [Line Items]
Mortgage payable - HSBC Bank N.A.	9,906,000	9,976,000
Less debt issuance costs	(86,000)	(90,000)
Long-term mortgage payable	9,820,000	9,886,000
Less current maturities	458,000	454,000
Long-term mortgage payable less current maturities	$ 9,362,000	$ 9,432,000

XML

Segment Information (Details Narrative)	3 Months Ended
	Mar. 31, 2026 Segment
Segment Information Details Narrative [Abstract]
Number of reportable business segments	3
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	Chief Operating Desicion Maker [Member]
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	The Company's CODM evaluates the performance of each operating segment based on segment revenues and operating income. Segment revenues are defined as total revenues, excluding inter-segment revenue. Segment operating earnings are defined as segment revenues, less cost of goods sold and operating expenses.

XML

Segment Information - Financial Data by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Segment Reporting Information [Line Items]
Net Sales	$ 52,301	$ 45,958
Less: Segment cost of sales	31,516	28,041
Less: Segment selling, general, and administrative expenses	19,039	15,491
Operating income	1,746	2,426
Interest expense, net	(486)	(397)
Other income (expense), net	(16)	90
Income before income taxes	1,244	2,119
Assets	195,243	163,039	$ 170,998
Additions to property, plant and equipment	1,889	1,353
Depreciation and amortization	1,971	1,501
United States Segment
Segment Reporting Information [Line Items]
Net Sales	43,768	39,122
Less: Segment cost of sales	26,659	23,700
Less: Segment selling, general, and administrative expenses	16,070	13,063
Operating income	1,039	2,359
Assets	171,504	143,808
Additions to property, plant and equipment	1,824	1,334
Depreciation and amortization	1,882	1,444
Canada Segment
Segment Reporting Information [Line Items]
Net Sales	3,700	3,185
Less: Segment cost of sales	2,135	1,985
Less: Segment selling, general, and administrative expenses	1,318	1,159
Operating income	247	41
Assets	10,766	9,713
Additions to property, plant and equipment	4	18
Depreciation and amortization	27	44
Europe Segment
Segment Reporting Information [Line Items]
Net Sales	4,833	3,651
Less: Segment cost of sales	2,722	2,356
Less: Segment selling, general, and administrative expenses	1,651	1,269
Operating income	460	26
Assets	12,973	9,518
Additions to property, plant and equipment	61	1
Depreciation and amortization	$ 62	$ 12

XML

Stock Based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]
Share-based compensation expense	$ 319,000	$ 413,000
Unrecognized compensation cost	$ 3,328,608
Unrecognized compensation cost recognition period	3 years

XML

Leases (Details Narrative) $ in Millions	3 Months Ended
	Mar. 31, 2026 USD ($)
Lessee Lease Description [Line Items]
Operating lease expense	$ 0.5
Cost of Goods Sold
Lessee Lease Description [Line Items]
Operating lease expense	0.2
Selling, General and Administrative Expenses
Lessee Lease Description [Line Items]
Operating lease expense	$ 0.3

XML

Leases - Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Leases Details [Abstract]
Operating lease cost	$ 513	$ 461
Operating lease - cash flow	$ 468	$ 464
Weighted-average remaining lease term	6 years	4 years
Weighted-average discount rate	7.00%	7.00%

XML

Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Future Minimum Lease Payments:
2026 (remaining)	$ 1,357
2027	1,668
2028	1,697
2029	993
2030	639
Thereafter	1,438
Total future minimum lease payments	7,792
Less: imputed interest	(1,243)
Present value of lease liabilities - current	1,373	$ 1,446
Present value of lease liabilities - non-current	$ 5,176	$ 5,532

XML

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Other Accrued Liabilities [Line Items]
Customer rebates	$ 7,543	$ 6,863
Accrued compensation	2,487	2,950
Dividend payable	610	609
Other	2,995	2,498
Total:	17,778	$ 12,920
My Medic Asset Acquisition
Other Accrued Liabilities [Line Items]
Holdback Liability	3,143
Contingent liability	$ 1,000

XML

Intangible Assets and Goodwill - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]
Tradename	$ 12,909	$ 12,909
Customer list	21,114	21,114
Non-compete	1,667	1,667
Patents	2,272	2,272
My Medic intangible assets	15,409
Subtotal	53,371	37,962
Less: Accumulated amortization	19,281	18,465
Translation adjustments	(69)	(24)
Intangible assets	34,021	19,473
Goodwill	9,908	9,908
Total:	$ 43,929	$ 29,381

XML

Intangible Assets and Goodwill (Details Narrative)	Mar. 31, 2026
Minimum
Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets, useful lives	5 years
Maximum
Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets, useful lives	15 years

XML

Inventories - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Inventory Disclosure [Abstract]
Finished goods	$ 49,937	$ 44,751
Work in process	395	305
Materials and supplies	13,054	14,796
Inventories	$ 63,386	$ 59,852

XML

Business Combination - Schedule of Preliminary Purchase Price Allocation to Assets Acquired (Details) - My Medic $ in Thousands	Jan. 15, 2026 USD ($)
Assets:
Accounts Receivable	$ 238
Inventory	2,662
Prepaid Expense	223
Property, Plant & Equipment	21
Intangibles	15,409
Total assets	$ 18,553

XML

Business Combination (Details Narrative) - USD ($)		3 Months Ended
	Jan. 15, 2026	Mar. 31, 2026
Business Acquisition [Line Items]
Amount paid to acquire business		$ 14,412,000
My Medic
Business Acquisition [Line Items]
Asset acquisition agreement date	Jan. 15, 2026
Purchase price	$ 18,600,000
Amount paid to acquire business	14,400,000
Business acquisition, contingent liability	4,100,000
Business combination contingent consideration liability holdback as a non- exclusive source of recovery primarily to satisfy indemnification claims	3,100,000
Revenue contributed		$ 3,400,000
My Medic | Revenue Milestone
Business Acquisition [Line Items]
Business acquisition, contingent liability	$ 1,000,000